Abstract
For many psychotropic drugs, pharmacogenetic polymorphisms are known to affect biotransformation and clinical outcome. In antidepressant drug treatment, most drugs are metabolized via the polymorphic cytochrome P450 enzymes CYP2D6 and CYP2C19. Huge differences in pharmacokinetic parameters have been consistently shown for many tricyclics, some SSRIs, and other antidepressant drugs. However, the effects on therapeutic drug efficacy and adverse events have been described controversially. Pharmacokinetic differences caused by genetic polymorphisms can be overcome by adapting the drug dosages and dosing intervals. Similar to bioequivalence studies, the aim to achieve similar plasma concentration time courses of antidepressants might help to reduce side effects and therapeutic failure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
